Michael Kragh
Symphogen (Denmark)(DK)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, Radiopharmaceutical Chemistry and Applications, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → The genomic landscape of response to EGFR blockade in colorectal cancer(2015)490 cited
- → Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy(2010)227 cited
- → Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses(2018)142 cited
- → CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models(2019)105 cited
- → Interleukin 21: combination strategies for cancer therapy(2008)103 cited
- → Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor(2011)92 cited
- → Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity(2015)84 cited
- → Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab(2013)80 cited
- → Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype(2020)80 cited
- → Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer(2015)77 cited